News

In an interview segment with Kirby, she described her views on the need for future research into povorcitinib for hidradenitis suppurativa patients, as well as her outlook on treatment.

Electroacupuncture also resulted in a greater relief for the majority of OIC symptoms and improved the quality of life for this patient population and had no effects on cancer pain and its opioid treatment dosage.

In the interview, Kirby discussed recent trial data on povorcitinib indicating significant decreases in total abscess and inflammatory nodule count for hidradenitis suppurativa patients.

The historic FDA approval of pegcetacoplan marks the first and only approved treatment for geographic atrophy. In a new interview, Dr. Wykoff expresses what approval means for patients with the debilitating disease.

A cohort study of 1.9 million infants links exposure to fine particulate matter (PM2.5) to an increased risk of emergency department visits during the first year of life, with preterm and full-term infants being most susceptible during their fourth and fifth months.

Patients who were PCR positive or likely colonized in the two-step era were 20 times less likely to be associated with treatment for CDI, without adversely impacting patient outcomes.

Chovatiya discussed his Winter Clinical Miami presentation, common concerns over black box warnings for JAK inhibitors, and unmet needs of alopecia areata patients.

In his latest HCPLive interview, regarding a presentation at Winter Clinical Miami, Chovatiya spoke about recent JAK inhibitor developments, alopecia areata, baricitinib, and more.

A study from Slovenia suggests a physical activity intervention that would require physical activity every day while at school was effective for reducing BMI and reversing obesity in young children.

Although the use of β-Blockers did not affect early-stage AMD, their long-term use was indicated to be protective against the risk of AMD among patients with hypertension.

The FDA assigned a PDUFA date of September 28, 2023 for the phentolamine ophthalmic solution 0.75%.

Phase 2 trial shows iron hydroxide adipate tartrate (IHAT) is non-inferior to ferrous sulfate (FeSO4) in correcting iron deficiency and hemoglobin response, with a lower incidence of moderate-severe diarrhea.

A new study indicates that OCTA-derived features of MNV disease activity may be useful biomarkers to confirm MNV stability in patients with treated stable nAMD.

Using the GWTG-HF registry, new data elucidates the differences in the likelihood of being prescribed GDMT among patients hospitalized with heart failure in rural compared to urban settings.

There was a 2.35-fold risk increase in PCCRC in the lowest ADR group compared to the highest.

The company announced more feedback from the FDA after receiving a Complete Response Letter last March.

An analysis of Veterans Affairs data from more than 20,000 people with diabetes provides an overview of the associations of CGM initiation with improved glycemic control and reduced hospitalization in this patient population.

In her latest HCPLive interview, Ablon discusses her Winter Clinical Miami dermatology conference presentation ‘Evaluating the Aesthetic Patient’ and its biggest takeaways.

HCV RNA positivity was significantly more prevalent in the male patient than it was for females in both adults and the general population after excluding high-risk groups.

How much do you know about opioid usage in patients with rheumatoid arthritis? Test your knowledge with this quiz.

A study examining the COVID-19 pandemic finds that substance use declined substantially across nearly all categories in 2018-2019 vs 2020 among youth and young adults.

A 0.18-mg implant may be an effective option in managing noninfectious uveitis affecting the posterior segment.

Influenza vaccination is especially crucial among children and adolescents with chronic medical conditions that put them at high risk for severe outcomes.

Baseline evidence of deep capillary nonperfusion in eyes with clinically referable NPDR may predict short-term complications with high accuracy.

An analysis of data from more than 5000 youths with T1D offers insight into the comparative ability of different treatment modalities for achieving glycemic control and optimal time in range.

There were no serious adverse events in the group of patients treated with colesevelam.

In another segment of her interview with HCPLive, Graber explored some of the latest treatment developments for acne and rosacea covered in her 2023 Winter Clinical Miami presentation.

Using data from nearly 2 million US patients with a documented COVID-19 infection, a new study provides an overview of the impact of vaccination, both full and partial, on risk of MACE following infection.